Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, announces that it has entered into a definitive agreement to be acquired by GTCR, a leading private equity firm with a long track record of investment expertise across healthcare and healthcare technology. “With its longstanding, blue chip customer relationships and a rich history of developing medical technologies that deliver enhanced performance and improved clinical outcomes, Surmodics is well-positioned for attractive, long-term growth and value creation,” said Sean Cunningham, Managing Director and Head of Healthcare at GTCR. “We look forward to partnering with the Surmodics team to continue to expand the company’s offering and broaden its reach.”
Read the full article: Surmodics Enters into Definitive Agreement to Be Acquired by GTCR for $43.00 Per Share in Cash //
Source: https://www.businesswire.com/news/home/20240529992714/en/Surmodics-Enters-into-Definitive-Agreement-to-be-Acquired-by-GTCR-for-43.00-Per-Share-in-Cash-Representing-an-Approximate-Equity-Value-of-627-Million